Does Neutrophil-to-Lymphocyte Ratio (NLR) Predict Pathologic Response to Neoadjuvant Chemoradiotherapy in Patients with Esophageal Squamous Cell Carcinoma?

Abstract

Background

Neoadjuvant chemoradiotherapy (nCRT), followed by surgery, is the current standard of care for patients with locally advanced esophageal squamous cell carcinoma. However, up to 30% of the patients do not respond to nCRT. Hence, a simple, cost-effective marker to predict response before initiation of nCRT is needed. Neutrophil-to-lymphocyte ratio (NLR) has been reported as a prognostic marker in various cancers. However, its role as a predictive marker in patients with esophageal SCC planned for nCRT has not been prospectively analyzed.

Materials and Methods

All consecutive patients with locally advanced (T1N1 and T2–T4a with or without nodal involvement) SCC planned for nCRT (CROSS protocol) followed by esophagectomy with total two field lymphadenectomy between December 2013 and December 2019 were included in this prospective analytical cohort study. NLR was calculated 1 week before starting the nCRT and was correlated with the histopathological response [Mandard tumor regression grade (TRG)].

Results

Of the 216 patients with esophageal cancer evaluated during the study period, 57 patients with SCC who fulfilled the inclusion criteria were included. A good pathologic response (TRG 1 and 2) to nCRT was seen in 28 (49.1%) patients. Using a ROC curve, the optimal cutoff value of pretherapy NLR for predicting good pathologic response was 2.33. With an NLR cutoff value of 2.33, 53.3% of patients had a good pathologic response to nCRT compared with 47.6% patients with NLR ≥ 2.33 (P = 0.77).

Conclusion

In patients with locally advanced esophageal SCC, NLR is not a useful marker to predict pathologic response to nCRT.

This is a preview of subscription content, log in to check access.

Fig. 1
Fig. 2

References

  1. 1.

    Shapiro J, van Lanschot JJB, Hulshof MCCM, van Hagen P, van Berge Henegouwen M, Wijnhoven BPL, van Laarhoven H, Nieuwenhuijzen GAP, Hospers GAP, Bonenkamp JJ, Cuesta MA, Blaisse RJB, Busch ORC, ten Kate F, Creemers GM, Punt CJA, Plukker JTM, Verheul HMW, Bilgen EJS, van Dekken H, van der Sangen M, Rozema T, Biermann K, Beukema JC, Piet AHM, van Rij C, Reinders JG, Tilanus HW, Steyerberg EW, van der Gaast A, CROSS study group; CROSS study group (2015). Neoadjuvant chemoradiotherapy plus surgery versus surgery alone for oesophageal or junctional cancer (CROSS): long-term results of a randomised controlled trial. Lancet Oncol 16:1090–1098.

  2. 2.

    Sjoquist KM, Burmeister BH, Smithers BM, et al; Australasian Gastro-Intestinal Trials Group. Survival after neoadjuvant chemotherapy or chemoradiotherapy for resectable oesophageal carcinoma: an updated meta-analysis. Lancet Oncol. 2011;12:681–92.

    Article  Google Scholar 

  3. 3.

    Chiam K, Mayne GC, Watson DI, Woodman RJ, Bright TF, Michael MZ, et al. Identification of microRNA biomarkers of response to neoadjuvant chemoradiotherapy in esophageal adenocarcinoma using next generation sequencing. Ann Surg Oncol. 2018;25:2731–8.

    Article  Google Scholar 

  4. 4.

    Wong C, Law S. Predictive factors in the evaluation of treatment response to neoadjuvant chemoradiotherapy in patients with advanced esophageal squamous cell cancer. J Thorac Dis. 2017;9:S773–80.

    Article  Google Scholar 

  5. 5.

    Carruthers R, Tho LM, Brown J, Kakumanu S, McCartney E, McDonald AC. Systemic inflammatory response is a predictor of outcome in patients undergoing preoperative chemoradiation for locally advanced rectal cancer. Color Dis. 2012;14:e701–7.

    CAS  Article  Google Scholar 

  6. 6.

    Kim YJ, Lee I, Chung YS, Nam EJ, Kim S, Kim SW, et al. Pretreatment neutrophil-to-lymphocyte ratio and its dynamic change during neoadjuvant chemotherapy as poor prognostic factors in advanced ovarian cancer. Obstet Gynecol Sci. 2018;61:227–34.

    Article  Google Scholar 

  7. 7.

    Liu D, Huang Y, Li L, Song J, Zhang L, Li W. High neutrophil-to-lymphocyte ratios confer poor prognoses in patients with small cell lung cancer. BMC Cancer. 2017;17:882.

    Article  Google Scholar 

  8. 8.

    Clarke KV, Amir E, Berman HK, Maganti M, Sridhar SS. Association between pretreatment neutrophil to lymphocyte ratio (NLR) and complete pathological response (pCR) in breast cancer patients treated with neoadjuvant chemotherapy (NACT). J Clin Oncol. 2015;33:e11588.

    Article  Google Scholar 

  9. 9.

    Kusumanto YH, Dam WA, Hospers GA, et al. Platelets and granulocytes, in particular the neutrophils, form important compartments for circulating vascular endothelial growth factor. Angiogenesis. 2003;6:283–7.

    CAS  Article  Google Scholar 

  10. 10.

    Pirozzolo G, Gisbertz SS, Castoro C, van Berge Henegouwen MI, Scarpa M. Neutrophil-to-lymphocyte ratio as prognostic marker in esophageal cancer: a systematic review and meta-analysis. J Thorac Dis. 2019;11:3136–45.

    Article  Google Scholar 

  11. 11.

    Zhang X, Jiang Y, Wang Y, Wang Z, Zhao L, Xue X, et al. Prognostic role of neutrophil-lymphocyte ratio in esophageal cancer: a systematic review and meta-analysis. Medicine (Baltimore). 2018;97:e13585.

    Article  Google Scholar 

  12. 12.

    Miyata H, Yamasaki M, Kurokawa Y, et al. Prognostic value of an inflammation-based score in patients undergoing pre-operative chemotherapy followed by surgery for esophageal cancer. Exp Ther Med. 2011;2:879–85.

    Article  Google Scholar 

  13. 13.

    Sato H, Yasuhiro T, Kawano T. Correlation between the pretherapeutic neutrophil to lymphocyte ratio and the pathologic response to neoadjuvant chemotherapy in patients with advanced esophageal cancer. World J Surg. 2012;36:617–22.

    Article  Google Scholar 

  14. 14.

    Powell AGMT, Chin C, Coxon AH, Chalishazar A, Christian A, Roberts SA, et al. Neutrophil to lymphocyte ratio as a predictor of response to neoadjuvant chemotherapy and survival in oesophageal adenocarcinoma. BJS Open. [Epub ahead of print]. 2020;4:416–23.

    CAS  Article  Google Scholar 

  15. 15.

    van Hagen P, Hulshof MC, van Lanschot JJ, Steyerberg EW, van Berge Henegouwen M, Wijnhoven BP, et al. Preoperative chemoradiotherapy for esophageal or junctional cancer. N Engl J Med. 2012;366:2074–84.

    Article  Google Scholar 

  16. 16.

    Sagiv JY, Michaeli J, Assi S, Mishalian I, Kisos H, Levy L, et al. Phenotypic diversity and plasticity in circulating neutrophil subpopulations in cancer. Cell Rep. 2015;10:562–73.

    CAS  Article  Google Scholar 

  17. 17.

    Giese MA, Hind LE, Huttenlocher A. Neutrophil plasticity in the tumor microenvironment. Blood. 2019;133:2159–67.

    CAS  Article  Google Scholar 

  18. 18.

    Peters JH, Meester TR, Stein HJ. Surgical therapy for cancer of the esophagus and cardia (1995). In: Castell DO; Ed. The Esophagus, 2nd ed. New York: Little, Brown. p.293–335.

  19. 19.

    Eisenhauer EA, Therasse P, Bogaerts J, et al. New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1). Eur J Cancer. 2009;45:228–47.

    CAS  Article  Google Scholar 

  20. 20.

    Sasikumar K, Kalayarasan R, Gnanasekaran S, et al (2020). Minimally invasive oesophagectomy with a total two-field lymphadenectomy after neoadjuvant chemoradiotherapy for locally advanced squamous cell carcinoma of the oesophagus: a prospective study. J minim access Surg Jan 9 [Epub ahead of print].

  21. 21.

    Anand S, Kalayarasan R, Chandrasekar S, Gnanasekaran S, Pottakkat B. Minimally invasive esophagectomy with thoracic duct resection post neoadjuvant chemoradiotherapy for carcinoma esophagus-impact on lymph node yield and hemodynamic parameters. J Gastrointest Cancer. 2019;50:230–5.

    Article  Google Scholar 

  22. 22.

    Mandard AM, Dalibard F, Mandard JC, Marnay J, Henry-Amar M, Petiot JF, et al. Pathologic assessment of tumor regression after preoperative chemoradiotherapy of esophageal carcinoma. Clinicopathologic Correlations Cancer. 1994;73:2680–6.

    CAS  PubMed  Google Scholar 

  23. 23.

    Amin MB, Edge S, Greene F, et al. (Eds.). AJCC cancer staging manual (8th edition). Springer International Publishing: American Joint Commission on Cancer; 2017.

  24. 24.

    Miyata H, Sugimura K, Yamasaki M, Makino T, Tanaka K, Morii E, et al. Clinical impact of the location of lymph node metastases after neoadjuvant chemotherapy for middle and lower thoracic esophageal cancer. Ann Surg Oncol. 2019;26:200–8.

    Article  Google Scholar 

  25. 25.

    Martin A, Seignez C, Racoeur C, Isambert N, Mabrouk N, Scagliarini A, et al. Tumor-derived granzyme B-expressing neutrophils acquire antitumor potential after lipid a treatment. Oncotarget. 2018;9:28364–78.

    Article  Google Scholar 

  26. 26.

    Finisguerra V, Di Conza G, Di Matteo M, et al. MET is required for the recruitment of anti-tumoural neutrophils. Nature. 2015;522:349–53.

    CAS  Article  Google Scholar 

Download references

Author information

Affiliations

Authors

Corresponding author

Correspondence to Raja Kalayarasan.

Ethics declarations

Conflict of Interest

The authors declare that they have no conflict of interest.

Additional information

Publisher’s Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Rights and permissions

Reprints and Permissions

About this article

Verify currency and authenticity via CrossMark

Cite this article

Anand, S., Bhati, G., Gurram, R. et al. Does Neutrophil-to-Lymphocyte Ratio (NLR) Predict Pathologic Response to Neoadjuvant Chemoradiotherapy in Patients with Esophageal Squamous Cell Carcinoma?. J Gastrointest Canc (2020). https://doi.org/10.1007/s12029-020-00445-5

Download citation

Keywords

  • Neutrophil-to-lymphocyte ratio
  • Esophageal cancer
  • Neoadjuvant therapy
  • Squamous cell carcinoma